Advancements in Melanoma Therapies: From Surgery to Immunotherapy.
Combination therapy
Immunotherapy
Melanoma
Targeted therapy
Treatment
Journal
Current treatment options in oncology
ISSN: 1534-6277
Titre abrégé: Curr Treat Options Oncol
Pays: United States
ID NLM: 100900946
Informations de publication
Date de publication:
27 Jul 2024
27 Jul 2024
Historique:
accepted:
14
06
2024
medline:
28
7
2024
pubmed:
28
7
2024
entrez:
27
7
2024
Statut:
aheadofprint
Résumé
Melanoma is defined as the most aggressive and deadly form of skin cancer. The treatment of melanoma depends on the disease stage, tumor location, and extent of its spread from its point of origin. Melanoma treatment has made significant advances, notably in the context of targeted and immunotherapies. Surgical resection is the main therapeutic option for earlystage melanoma, and it provides favourable outcomes. With disease metastasis, systemic treatments such as immunotherapy and targeted therapy become increasingly important. The identification of mutations that lead to melanoma has influenced treatment strategies. Targeted therapies focusing on these mutations offer improved response rates and fewer toxicities than conventional chemotherapy. Furthermore, developing immunotherapies, including checkpoint inhibitors and tumor-infiltrating lymphocyte (TIL) therapies, has demonstrated encouraging outcomes in effectively combating cancer cells. These therapeutic agents demonstrate superior effectiveness and a more tolerable side-effect profile, improving the quality of life for patients receiving treatment. The future of melanoma treatment may involve a multimodal approach consisting of a combination of surgery, targeted therapy, and immunotherapy adapted to each patient's profile. This approach may improve survival rates and health outcomes.
Identifiants
pubmed: 39066854
doi: 10.1007/s11864-024-01239-8
pii: 10.1007/s11864-024-01239-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Karimkhani C, Green AC, Nijsten T, Weinstock MA, Dellavalle RP, Naghavi M, Fitzmaurice C. The global burden of melanoma: results from the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134–40.
pubmed: 28369739
pmcid: 5575560
doi: 10.1111/bjd.15510
Duarte AF, Sousa-Pinto B, Azevedo LF, Barros AM, Puig S, Malvehy J, et al. Clinical ABCDE rule for early melanoma detection. Eur J Dermatol. 2021;31(6):771–8.
pubmed: 35107069
doi: 10.1684/ejd.2021.4171
Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA: a Cancer J Clin. 1985;35(3):130–51.
Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292(22):2771–6.
pubmed: 15585738
doi: 10.1001/jama.292.22.2771
Domingues B, Lopes JM, Soares P, Pópulo H. Melanoma treatment in review. ImmunoTargets Ther. 2018;7(null):35–49. https://doi.org/10.2147/ITT.S134842 .
Heo JR, Kim NH, Cho J, Choi KC. Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma. Oncol Rep. 2016;36(4):1779–86.
pubmed: 27573048
doi: 10.3892/or.2016.5032
Tyrell R, Antia C, Stanley S, Deutsch GB. Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. Melanoma management. 2017;4(1):61–8.
pubmed: 30190905
pmcid: 6094597
doi: 10.2217/mmt-2016-0018
Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38(33):3947–70.
pubmed: 32228358
doi: 10.1200/JCO.20.00198
Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(4):367–402.
doi: 10.6004/jnccn.2019.0018
Keilholz U, Ascierto P, Dummer R, Robert C, Lorigan P, Van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31(11):1435–48.
pubmed: 32763453
doi: 10.1016/j.annonc.2020.07.004
Li J, Wang Y, Liang R, An X, Wang K, Shen G, et al. Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomed: Nanotechnol, Biol Med. 2015;11(3):769–94.
doi: 10.1016/j.nano.2014.11.006
Midorikawa Y, Tsuji S, Takayama T, Aburatani H. Genomic approach towards personalized anticancer drug therapy. Pharmacogenomics. 2012;13(2):191–9.
pubmed: 22256868
doi: 10.2217/pgs.11.157
Maleki LA, Baradaran B, Majidi J, Mohammadian M, Shahneh FZ. Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Hum Antibodies. 2013;22(1–2):9–13.
pubmed: 24284304
doi: 10.3233/HAB-130266
Newcomer K, Robbins KJ, Perone J, Hinojosa FL, Chen D, Jones S, et al. Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. Curr Probl Surg. 2022;59(1): 101030.
pubmed: 35033317
doi: 10.1016/j.cpsurg.2021.101030
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.
Raigani S, Cohen S, Boland GM. The role of surgery for melanoma in an era of effective systemic therapy. Curr Oncol Rep. 2017;19:1–5.
doi: 10.1007/s11912-017-0575-8
Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012;19:2547–55.
pubmed: 22648554
pmcid: 3405182
doi: 10.1245/s10434-012-2398-z
Lwin TM, Kaelberer Z, Ruan M, Molina G, Boland G. Surgical utilization and outcomes for patients with stage IV melanoma in the modern immunotherapy era. Ann Surg Oncol. 2023;30(8):5005–12.
Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, et al. NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines. J Nat Compr Cancer Netw. 2021;19(4):364–76.
doi: 10.6004/jnccn.2021.0018
Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer J (Sudbury, Mass). 2012;18(2):176.
doi: 10.1097/PPO.0b013e31824bc981
Hsueh EC, Gupta RK, Yee R, Leopoldo ZC, Qi K, Morton DL. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol. 2000;7:232–8.
pubmed: 10791855
doi: 10.1007/BF02523659
Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline–Update 2016. Eur J Cancer. 2016;63:201–17.
pubmed: 27367293
doi: 10.1016/j.ejca.2016.05.005
Morris KT, Marquez CM, Holland JM, Vetto JT. Prevention of local recurrence after surgical debulking of nodal and subcutaneous melanoma deposits by hypofractionated radiation. Ann Surg Oncol. 2000;7:680–4.
pubmed: 11034246
doi: 10.1007/s10434-000-0680-y
Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non–small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–72.
pubmed: 24563870
pmcid: 3930458
doi: 10.1158/2326-6066.CIR-13-0115
Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Rad Oncol* Biol* Physics. 2004;58(3):862–70.
doi: 10.1016/j.ijrobp.2003.09.012
Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3(5): e28780.
pubmed: 25083318
pmcid: 4106166
doi: 10.4161/onci.28780
Xu J, He J, He J, He Y, Zhang D, Kong R, Dan K. The abscopal effect of anti-CD95 and radiotherapy in melanoma. Discover Oncology. 2023;14(1):1–11.
doi: 10.1007/s12672-023-00682-7
Zager JS, Sondak VK, Kudchadkar R. Melanoma. 1st ed. Oxford University Press; 2016.
Berthenet K, Ferrer CC, Fanfone D, Popgeorgiev N, Neves D, Bertolino P, et al. Failed apoptosis enhances melanoma cancer cell aggressiveness. Cell Reports. 2020;31(10):107731.
pubmed: 32521256
doi: 10.1016/j.celrep.2020.107731
Serrone L, Zeuli M, Sega F, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res: CR. 2000;19(1):21–34.
pubmed: 10840932
Huttunen KM, Mahonen N, Raunio H, Rautio J. Cytochrome P450-activated prodrugs: targeted drug delivery. Curr Med Chem. 2008;15(23):2346–65.
pubmed: 18855665
doi: 10.2174/092986708785909120
Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007;12(9):1114–23.
pubmed: 17914081
doi: 10.1634/theoncologist.12-9-1114
Tas F, Erturk K. Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma. J Oncol Pharm Pract. 2021;27(1):40–5.
pubmed: 32169004
doi: 10.1177/1078155220909426
Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res. 2007;56(4):275–87.
pubmed: 17897837
doi: 10.1016/j.phrs.2007.08.003
Middleton MR, Grob J, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158.
pubmed: 10623706
doi: 10.1200/JCO.2000.18.1.158
Fuertes M, Castilla J, Alonso C, Prez J. Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 2003;10(3):257–66.
pubmed: 12570712
doi: 10.2174/0929867033368484
Sharp CN. Developing a more clinically-relevant mouse model of cisplatin-induced nephrotoxicity. Electronic Theses and Dissertations. 2016;(null):2524. https://doi.org/10.18297/etd/2524 .
Ursic K, Kos S, Kamensek U, Cemazar M, Scancar J, Bucek S, et al. Comparable effectiveness and immunomodulatory actions of oxaliplatin and cisplatin in electrochemotherapy of murine melanoma. Bioelectrochemistry. 2018;119:161–71.
pubmed: 29024870
doi: 10.1016/j.bioelechem.2017.09.009
Glover D, Ibrahim J, Kirkwood J, Glick J, Karp D, Stewart J, et al. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). Melanoma Res. 2003;13(6):619–26.
pubmed: 14646626
doi: 10.1097/00008390-200312000-00012
Casper ES, Bajorin D. Phase II trial of carboplatin in patients with advanced melanoma. Invest New Drugs. 1990;8:187–90.
pubmed: 1696568
doi: 10.1007/BF00177256
Al Saqr A, Annaji M, Poudel I, Aldawsari MF, Alrbyawi H, Mita N, et al. Topical delivery of diacetyl boldine in a microemulsion formulation for chemoprotection against melanoma. Pharmaceutics. 2023;15(3):901.
pubmed: 36986762
pmcid: 10054442
doi: 10.3390/pharmaceutics15030901
Quéreux G, Dréno B. Fotemustine for the treatment of melanoma. Expert Opin Pharmacother. 2011;12(18):2891–904.
pubmed: 22077794
doi: 10.1517/14656566.2011.633513
Selimovic D, Badura HE, El-Khattouti A, Soell M, Porzig BB, Spernger A, et al. Vinblastine-induced apoptosis of melanoma cells is mediated by Ras homologous A protein (Rho A) via mitochondrial and non-mitochondrial-dependent mechanisms. Apoptosis. 2013;18:980–97.
pubmed: 23564313
doi: 10.1007/s10495-013-0844-4
Lin K-I, Lin C-C, Kuo S-M, Lai J-C, Wang Y-Q, You H-L, et al. Carnosic acid impedes cell growth and enhances anticancer effects of carmustine and lomustine in melanoma. Bioscience Rep. 2018;38(4):BSR20180005.
doi: 10.1042/BSR20180005
Oliveira RR, Cintra ER, Sousa-Junior AA, Moreira LC, da Silva AC, de Souza ALR, et al. Paclitaxel-Loaded Lipid-Coated Magnetic Nanoparticles for Dual Chemo-Magnetic Hyperthermia Therapy of Melanoma. Pharmaceutics. 2023;15(3):818.
pubmed: 36986678
pmcid: 10055620
doi: 10.3390/pharmaceutics15030818
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17(9):2745.
pubmed: 10561349
doi: 10.1200/JCO.1999.17.9.2745
Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol. 2005;6(2):93–102.
pubmed: 15683818
doi: 10.1016/S1470-2045(05)01735-3
Lazaroff J, Bolotin D. Targeted therapy and immunotherapy in melanoma. Dermatol Clin. 2023;41(1):65–77.
Patel H, Yacoub N, Mishra R, White A, Yuan L, Alanazi S, Garrett JT. Current advances in the treatment of BRAF-mutant melanoma. Cancers. 2020;12(2):482.
pubmed: 32092958
pmcid: 7072236
doi: 10.3390/cancers12020482
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.
pubmed: 17496922
doi: 10.1038/sj.onc.1210421
Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018;31(1):24–38.
pubmed: 29148538
doi: 10.1038/modpathol.2017.104
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.
pubmed: 21639808
pmcid: 3549296
doi: 10.1056/NEJMoa1103782
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32.
pubmed: 24508103
pmcid: 4382632
doi: 10.1016/S1470-2045(14)70012-9
Chapman PB, Robert C, Larkin J, Haanen J, Ribas A, Hogg D, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28(10):2581–7.
pubmed: 28961848
pmcid: 5834156
doi: 10.1093/annonc/mdx339
Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. The Lancet. 2012;380(9839):358–65.
doi: 10.1016/S0140-6736(12)60868-X
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–27.
pubmed: 30219628
doi: 10.1016/S1470-2045(18)30497-2
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17. https://doi.org/10.1200/jco.1996.14.1.7 .
doi: 10.1200/jco.1996.14.1.7
pubmed: 8558223
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105.
pubmed: 10561265
doi: 10.1200/JCO.1999.17.7.2105
Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. The Lancet. 2008;372(9633):117–26.
doi: 10.1016/S0140-6736(08)61033-8
Hodi FS, O’day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England J Med. 2010;363(8):711–23.
doi: 10.1056/NEJMoa1003466
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.
pubmed: 22663011
doi: 10.1056/NEJMoa1203421
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.
pubmed: 25891173
doi: 10.1056/NEJMoa1503093
Robert C, Carlino MS, McNeil C, Ribas A, Grob J-J, Schachter J, et al. Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol. 2023;41(24):3998–4003.
pubmed: 37348035
doi: 10.1200/JCO.22.01599
Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.
pubmed: 25795410
doi: 10.1016/S1470-2045(15)70076-8
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.
pubmed: 25399552
doi: 10.1056/NEJMoa1412082
Robert C, Long GV, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, et al. Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma. J Clin Oncol. 2020;38(33):3937.
pubmed: 32997575
pmcid: 7676881
doi: 10.1200/JCO.20.00995
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56.
pubmed: 28889792
pmcid: 5706778
doi: 10.1056/NEJMoa1709684
Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. J Clin Oncol. 2021;39(15_suppl):9506. https://doi.org/10.1200/JCO.2021.39.15_suppl.9506 .
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.
pubmed: 27480103
doi: 10.1016/S1470-2045(16)30122-X
Ascierto PA, Dréno B, Larkin J, Ribas A, Liszkay G, Maio M, et al. 5-year outcomes with cobimetinib plus vemurafenib in BRAF V600 mutation–positive advanced melanoma: extended follow-up of the coBRIM study. Clin Cancer Res. 2021;27(19):5225–35.
pubmed: 34158360
pmcid: 9401485
doi: 10.1158/1078-0432.CCR-21-0809
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.
pubmed: 26014293
doi: 10.1200/JCO.2014.58.3377
Andtbacka RH, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma. J Immunother Cancer. 2019;7(1):1–11.
doi: 10.1186/s40425-019-0623-z
Milhem MM, Harrington KJ, Collichio FA, Amatruda T, Chesney JA, Agarwala SS, et al. Progression-free survival (PFS) in unresectable melanoma patients (pts) treated with talimogene laherparepvec (T-VEC) versus granulocyte macrophage colony-stimulating factor (GM-CSF) in OPTiM. Am Soc Clin Oncol. 2019;37:9524.
doi: 10.1200/JCO.2019.37.15_suppl.9524
Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2020;395(10240):1835–44.
doi: 10.1016/S0140-6736(20)30934-X
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. New England J Med. 2022;386(1):24–34.
doi: 10.1056/NEJMoa2109970
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12):e005755.
Medina T, Chesney J, Whitman E, Kluger H, Thomas S, Sarnaik A, et al. 119O Long-term efficacy and patterns of response of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: A 4-year analysis of the C-144–01 study. Immuno-Oncol Technol. 2023;20:100591.
doi: 10.1016/j.iotech.2023.100591
Luebker SA, Koepsell SA. Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies. Front Oncol. 2019;9:268.
pubmed: 31058079
pmcid: 6478763
doi: 10.3389/fonc.2019.00268
Grimaldi AM, Simeone E, Festino L, Vanella V, Strudel M, Ascierto PA. MEK inhibitors in the treatment of metastatic melanoma and solid tumors. Am J Clin Dermatol. 2017;18:745–54.
pubmed: 28537004
doi: 10.1007/s40257-017-0292-y
Parmiani G, Castelli C, Santinami M, Rivoltini L. Melanoma immunology: past, present and future. Curr Opin Oncol. 2007;19(2):121–7.
pubmed: 17272984
doi: 10.1097/CCO.0b013e32801497d7
Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in Melanoma: Recent advances and future directions. Cancers. 2023;15(4):1106.
pubmed: 36831449
pmcid: 9954703
doi: 10.3390/cancers15041106
Onitilo AA, Wittig JA. Principles of immunotherapy in melanoma. Surgical Clinics. 2020;100(1):161–73.
pubmed: 31753110
Sadreddini S, Baradaran B, Aghebati-Maleki A, Sadreddini S, Shanehbandi D, Fotouhi A, Aghebati-Maleki L. Immune checkpoint blockade opens a new way to cancer immunotherapy. J Cell Physiol. 2019;234(6):8541–9.
pubmed: 30511409
doi: 10.1002/jcp.27816
Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res. 2012;65(1):9–22.
pubmed: 21930211
doi: 10.1016/j.phrs.2011.09.002
Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.
pubmed: 30115704
doi: 10.1158/2159-8290.CD-18-0367
Sorkhabi AD, Sarkesh A, Fotouhi A, Saeedi H, Aghebati-Maleki L. Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma. IUBMB Life. 2022;74(9):908–17.
pubmed: 35638098
doi: 10.1002/iub.2655
Kähler KC, Hassel JC, Heinzerling L, Loquai C, Thoms KM, Ugurel S, et al. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma–an update. JDDG: J der Deutschen Dermatologischen Gesellschaft. 2020;18(6):582–609.
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727.
pubmed: 32266087
pmcid: 7136921
Pourakbari R, Hajizadeh F, Parhizkar F, Aghebati-Maleki A, Mansouri S, Aghebati-Maleki L. Co-stimulatory agonists: an insight into the immunotherapy of cancer. EXCLI J. 2021;20:1055.
pubmed: 34267616
pmcid: 8278219
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167.
pubmed: 20516446
pmcid: 4834717
doi: 10.1200/JCO.2009.26.7609
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
pubmed: 22658127
pmcid: 3544539
doi: 10.1056/NEJMoa1200690
Gambichler T, Schröter U, Höxtermann S, Susok L, Stockfleth E, Becker J. Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade. Br J Dermatol. 2020;182(5):1214–20.
pubmed: 31361026
doi: 10.1111/bjd.18379
Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y, Chen H. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5–6):176.
pubmed: 30603054
pmcid: 6305110
doi: 10.18632/genesandcancer.180
Ferrara N, Hillan KJ, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discovery. 2004;3(5):391–400.
pubmed: 15136787
doi: 10.1038/nrd1381
Gitaygoren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun. 1993;190(3):702–9.
pubmed: 8439321
doi: 10.1006/bbrc.1993.1106
Corrie P, Basu B, Ahmad ZK. Targeting angiogenesis in melanoma: prospects for the future. Ther Adv Med Oncol. 2010;2(6):367–80.
pubmed: 21789148
pmcid: 3126030
doi: 10.1177/1758834010380101
Perez DG, Suman VJ, Fitch TR, Amatruda T III, Morton RF, Jilani SZ, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009;115(1):119–27.
pubmed: 19090009
doi: 10.1002/cncr.23987
Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007;14:2367–76.
pubmed: 17534686
doi: 10.1245/s10434-007-9389-5
Banks PD, Lasocki A, Lau PK, Sandhu S, McArthur G, Shackleton M. Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. Health Science Reports. 2019;2(3): e115.
pubmed: 30937392
pmcid: 6427059
doi: 10.1002/hsr2.115
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2(7):632–42.
pubmed: 24838938
pmcid: 4306338
doi: 10.1158/2326-6066.CIR-14-0053
Slingluff CL Jr, Petroni GR, Molhoek KR, Brautigan DL, Chianese-Bullock KA, Shada AL, et al. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res. 2013;19(13):3611–20.
pubmed: 23620404
pmcid: 3700572
doi: 10.1158/1078-0432.CCR-12-3919
Corrie PG, Marshall A, Nathan P, Lorigan P, Gore M, Tahir S, et al. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol. 2018;29(8):1843–52.
pubmed: 30010756
pmcid: 6096737
doi: 10.1093/annonc/mdy229
Yan X, Sheng X, Chi Z, Si L, Cui C, Kong Y, et al. Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma. J Clin Oncol. 2021;39(8):881–9.
pubmed: 33444116
doi: 10.1200/JCO.20.00902
Delbaldo C, Raymond E, Vera K, Hammershaimb L, Kaucic K, Lozahic S, et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against α v β 3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs. 2008;26:35–43.
pubmed: 17876527
doi: 10.1007/s10637-007-9077-0
Weis SM, Cheresh DA. αV integrins in angiogenesis and cancer. Cold Spring Harbor Perspect Med. 2011;1(1):a006478.
doi: 10.1101/cshperspect.a006478
Petitclerc E, Strömblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, et al. Integrin αvβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Can Res. 1999;59(11):2724–30.
Arias-Mejias SM, Warda KY, Quattrocchi E, Alonso-Quinones H, Sominidi-Damodaran S, Meves A. The role of integrins in melanoma: a review. Int J Dermatol. 2020;59(5):525–34.
pubmed: 32157692
pmcid: 7167356
doi: 10.1111/ijd.14850
Nip J, Brodt P. The role of the integrin vitronectin receptor, α v β 3 in melanoma metastasis. Cancer Metastasis Rev. 1995;14:241–52.
pubmed: 8548872
doi: 10.1007/BF00690295
Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. Multiple roles for platelet GPIIb/IIIa and αvβ3 integrins in tumor growth, angiogenesis, and metastasis. Can Res. 2002;62(10):2824–33.
Hersey P, Sosman J, O’Day S, Richards J, Bedikian A, Gonzalez R, et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3,±dacarbazine in patients with stage IV metastatic melanoma. Cancer: Interdiscip Int J Am Cancer Soc. 2010;116(6):1526–34.
doi: 10.1002/cncr.24821
Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015;42(4):539–48.
Ardolino M, Hsu J, Raulet DH. Cytokine treatment in cancer immunotherapy. Oncotarget. 2015;6(23):19346.
pubmed: 26305981
pmcid: 4637281
doi: 10.18632/oncotarget.5095
Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):377–90.
pubmed: 25200249
doi: 10.1016/j.cytogfr.2014.07.018
Bentebibel S-E, Diab A. Cytokines in the Treatment of Melanoma. Curr Oncol Rep. 2021;23(7):83.
pubmed: 34003395
doi: 10.1007/s11912-021-01064-4
Majidpoor J, Mortezaee K. Interleukin-2 therapy of cancer-clinical perspectives. Int Immunopharmacol. 2021;98:107836.
pubmed: 34218217
doi: 10.1016/j.intimp.2021.107836
Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90.
pubmed: 22343569
doi: 10.1038/nri3156
Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–8.
pubmed: 24907378
doi: 10.4049/jimmunol.1490019
Zhou Y, Quan G, Liu Y, Shi N, Wu Y, Zhang R, et al. The application of Interleukin-2 family cytokines in tumor immunotherapy research. Front Immunol. 2023;14:1090311.
pubmed: 36936961
pmcid: 10018032
doi: 10.3389/fimmu.2023.1090311
Davar D, Wang H, Chauvin J-M, Pagliano O, Fourcade JJ, Ka M, et al. Phase Ib/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma. J Clin Oncol. 2018;36(35):3450.
pmcid: 6286160
doi: 10.1200/JCO.18.00632
Rostamizadeh L, Molavi O, Rashid M, Ramazani F, Baradaran B, Lavasanaifar A, Lai R. Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands. BioImpacts: BI. 2022;12(3):261.
pubmed: 35677663
pmcid: 9124882
Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28.
pubmed: 35303904
pmcid: 8931585
doi: 10.1186/s13045-022-01247-x
Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, Sparks FC. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180(4):635.
pubmed: 4412271
pmcid: 1344159
doi: 10.1097/00000658-197410000-00029
Motl SE. Technology evaluation: Canvaxin, John Wayne Cancer Institute/CancerVax. Curr Opin Mol Ther. 2004;6(1):104–11.
pubmed: 15011788
Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol. 1998;25(6):623–35.
Martinez-Perez D, Viñal D, Solares I, Espinosa E, Feliu J. Gp-100 as a novel therapeutic target in uveal melanoma. Cancers. 2021;13(23):5968.
pubmed: 34885078
pmcid: 8656894
doi: 10.3390/cancers13235968
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4(3):321–7.
pubmed: 9500606
pmcid: 2064864
doi: 10.1038/nm0398-321
Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27.
pubmed: 21631324
pmcid: 3517182
doi: 10.1056/NEJMoa1012863
Nin DS, Deng L-W. Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer. Cells. 2023;12(6):926.
pubmed: 36980267
pmcid: 10047177
doi: 10.3390/cells12060926
van Baren N, Bonnet M-C, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol. 2005;23(35):9008–21.
pubmed: 16061912
doi: 10.1200/JCO.2005.08.375
Bonehill A, Van Nuffel AM, Corthals J, Tuyaerts S, Heirman C, François V, et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res. 2009;15(10):3366–75.
pubmed: 19417017
doi: 10.1158/1078-0432.CCR-08-2982
Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother. 2011;34(5):448–56.
pubmed: 21577140
doi: 10.1097/CJI.0b013e31821dcb31
Grob J-J, Mortier L, D’Hondt L, Grange F, Baurain J, Dréno B, et al. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. ESMO open. 2017;2(5): e000203.
pubmed: 29177094
pmcid: 5687540
doi: 10.1136/esmoopen-2017-000203
Tiptiri-Kourpeti A, Spyridopoulou K, Pappa A, Chlichlia K. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy. Pharmacol Ther. 2016;165:32–49.
pubmed: 27235391
doi: 10.1016/j.pharmthera.2016.05.004
Hawkins WG, Gold JS, Dyall R, Wolchok JD, Hoos A, Bowne WB, et al. Immunization with DNA coding for gp100 results in CD4+ T-cell independent antitumor immunity. Surgery. 2000;128(2):273–80.
pubmed: 10923004
doi: 10.1067/msy.2000.107421
Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Can Res. 1997;57(14):2865–9.
Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther. 2007;15(11):2044–50.
pubmed: 17726460
doi: 10.1038/sj.mt.6300290
Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803–8.
pubmed: 25837513
pmcid: 4549796
doi: 10.1126/science.aaa3828
Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology. 2015;4(8): e1019197.
pubmed: 26405571
pmcid: 4570143
doi: 10.1080/2162402X.2015.1019197
Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, et al. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology. 2016;5(11): e1232237.
pubmed: 27999747
pmcid: 5139630
doi: 10.1080/2162402X.2016.1232237
Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13(6):1383.
pubmed: 33803762
pmcid: 8003308
doi: 10.3390/cancers13061383
Antohe M, Nedelcu RI, Nichita L, Popp CG, Cioplea M, Brinzea A, et al. Tumor infiltrating lymphocytes: The regulator of melanoma evolution. Oncol Lett. 2019;17(5):4155–61.
pubmed: 30944610
pmcid: 6444298
Wu R, Forget M-A, Chacon J, Bernatchez C, Haymaker C, Chen JQ, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer journal (Sudbury, Mass). 2012;18(2):160.
pubmed: 22453018
doi: 10.1097/PPO.0b013e31824d4465
Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol. 2019;10:2250.
pubmed: 31681259
pmcid: 6798078
doi: 10.3389/fimmu.2019.02250
Monberg TJ, Borch TH, Svane IM, Donia M. TIL therapy: facts and hopes. Clin Cancer Res. 2023;29(17):3275–83.
pubmed: 37058256
doi: 10.1158/1078-0432.CCR-22-2428
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319(25):1676–80.
pubmed: 3264384
doi: 10.1056/NEJM198812223192527
Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. JNCI: J Nat Cancer Inst. 1994;86(15):1159–66.
pubmed: 8028037
doi: 10.1093/jnci/86.15.1159
Keam SJ. Lifileucel: First approval. Mol Diagn Ther. 2024;28(3):339–44.
Biotherapeutics I. World’s first TIL therapy approved. Nat Biotechnol. 2024;42:347–54.